Literature DB >> 3036827

Class II genes of the human major histocompatibility complex. The DO beta gene is a divergent member of the class II beta gene family.

B Servenius, L Rask, P A Peterson.   

Abstract

A novel class II beta chain gene is described. This gene, tentatively called DO beta, displays considerably less polymorphism than beta genes of the DP, DQ, and DR loci. The nucleotide sequence of the DO beta gene is strikingly similar to that of the previously identified murine A beta 2 gene. The DO beta gene displays the same exon/intron organization as other beta genes although the fifth exon and the translated portion of the sixth exon are longer than in other genes. A striking feature of the amino acid sequence deduced from the DO beta gene sequence is the pronounced hydrophobicity of the NH2-terminal region. This feature distinguishes the putative DO beta chain from other class II beta chains and raises the possibility that DO beta chains may interact with an alpha chain that is structurally different from those of the DP, DQ, and DR loci. It further suggests that the putative DO molecule may have a function different from those of other class II antigens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036827

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Transcriptional control of the invariant chain gene involves promoter and enhancer elements common to and distinct from major histocompatibility complex class II genes.

Authors:  L Zhu; P P Jones
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

2.  X-box-binding proteins positively and negatively regulate transcription of the HLA-DRA gene through interaction with discrete upstream W and V elements.

Authors:  J P Cogswell; P V Basta; J P Ting
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 3.  Transcriptional regulation of HLA class-II genes.

Authors:  B M Peterlin; G Andersson; E Lötscher; S Tsang
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

4.  B-cell factor 1 is required for optimal expression of the DRA promoter in B cells.

Authors:  C F Voliva; A Aronheim; M D Walker; B M Peterlin
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

5.  A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM.

Authors:  Francis Deshaies; Alexandre Brunet; Djibril A Diallo; Lisa K Denzin; Angela Samaan; Jacques Thibodeau
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-22       Impact factor: 11.205

6.  Conservation of the promoter region of DRA-like genes from nonhuman primates.

Authors:  L K Gaur; E R Heise; J P Ting
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

7.  Divergent patterns of selection on the DAB and DXB MHC class II loci in Xiphophorus fishes.

Authors:  Kyle Summers; Kelly E Roney; Jack da Silva; Gerald Capraro; Brandon J Cuthbertson; Steven Kazianis; Gil G Rosenthal; Michael J Ryan; Thomas J McConnell
Journal:  Genetica       Date:  2008-07-04       Impact factor: 1.082

8.  Affinity-purified CCAAT-box-binding protein (YEBP) functionally regulates expression of a human class II major histocompatibility complex gene and the herpes simplex virus thymidine kinase gene.

Authors:  N J Zeleznik-Le; J C Azizkhan; J P Ting
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

9.  The MHC class II E beta promoter: a complex arrangement of positive and negative elements determines B cell and interferon-gamma (IFN-gamma) regulated expression.

Authors:  D Thanos; M Gregoriou; D Stravopodis; K Liapaki; T Makatounakis; J Papamatheakis
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

10.  Exon-intron organization of Xenopus MHC class II beta chain genes.

Authors:  F Kobari; K Sato; B P Shum; S Tochinai; M Katagiri; T Ishibashi; L Du Pasquier; M F Flajnik; M Kasahara
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.